Patent Publication Number: US-2005123478-A1

Title: Agent for measurement of singlet oxygen

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS  
      This application is a continuation of application Ser. No. 10/362,214, filed Aug. 31, 2001, which is the National Stage of International Patent Application No. PCT/JP01/07527, filed Aug. 31, 2001 and claims priority under 35 U.S.C. §119 of Japanese Patent Application Nos. 2000-263067, filed Aug. 31, 2000 and 2000-308581 filed Oct. 10, 2000. Moreover, the disclosures of U.S. patent application Ser. No. 10/362,214 and International Patent Application No. PCT/JP01/07527 are expressly incorporated by reference herein in their entireties. 
    
    
     TECHNICAL FIELD  
      The present invention relates to a compound or a salt thereof useful as an agent for measurement of singlet oxygen. The present invention also relates to an agent for measurement of singlet oxygen comprising the aforementioned compound or a salt thereof.  
      Background Art  
      It is known that, in living bodies and life phenomena, free radical species such as nitrogen monoxide are acting as a second messenger for signal transduction, and they exerts various physiological functions, for example, control of blood pressure in the circulatory system and the like. It has also been revealed that superoxides and hydrogen peroxide as active oxygen species also exert important physiological functions in the immune system and the like. However, importance of singlet oxygen as a physiologically active species, which has an analogous electronic structure, has little been elucidated so far.  
      Recently, singlet oxygen has been revealed to be a reactive species of photodynamic therapy, which is one of cancer therapies, and it has been suggested that various kinds of oxidases, peroxidases and the like are generating singlet oxygen in living bodies. Furthermore, it has also been revealed that oxygen molecules act as a sensor and have signal-like actions, and therefore, singlet oxygen is also suggested to have possible responsibility for important physiological functions in living bodies.  
      Among organs, skin suffers from direct contacts with outside air, and is a noticeably peculiar organ from a viewpoint of oxygen stress. It has been pointed out that, because skin is always exposed to oxygen and ultraviolet rays, skin lies in an environment in which oxidative damages likely occur due to active oxygens generated by ultraviolet rays or lipid peroxides generated thereby. It is suggested that accumulation of these oxidative damages is one of factors of skin retrogradation. Singlet oxygen is suggested to participate most frequently among active oxygens, however, no report has been made so far about direct measurement of singlet oxygen produced by skin-related cells.  
      Ten or more different methods are conventionally known as methods for measurement of singlet oxygen in living bodies, which include the chemiluminescence method, the electron spin resonance (ESR) method, the luminescence method and the like. However, these methods in common give only low specificity and sensitivity, and thus they are not reliable methods (as for the method for specific detection of singlet oxygen, see, Nagano, T., et al., Free radicals in Clinical Medicine, Vol. 7, pp. 35-41, 1993, etc.). Therefore, it has been desired to develop a method for measurement of singlet oxygen superior in specificity and sensitivity to study the involvement of singlet oxygen in life phenomena.  
      The inventors of the present invention proposed compounds prepared by introduction of anthracene derivatives into fluorescein as means for measurement of singlet oxygen superior in specificity and sensitivity (International Patent Publication WO99/51586). By using these anthracene derivatives, singlet oxygen localized in particular cells or tissues can be measured based on a bioimaging technique. The anthracene derivatives are excellent in specificity and sensitivity, however, they have a problem that a fluorescent endoperoxide compound, which is generated by a reaction with singlet oxygen, is unstable against light. Further, these anthracene derivatives are highly lipid-soluble, which raises a problem that, for example, they are localized in cell membranes when loaded onto cells and hardly be distributed uniformly in cells. Therefore, it has been desired to develop an agent for measurement of singlet oxygen which can generate a light-stable fluorescent substance and can be uniformly distributed in cells.  
     DISCLOSURE OF THE INVENTION  
      An object of the present invention is to provide a compound useful as an agent for measurement of singlet oxygen. More specifically, an object of the present invention is to provide a compound useful as an agent for measurement of singlet oxygen which can generate a light-stable fluorescent substance and can be uniformly distributed in a cell. Another object of the present invention is to provide an agent for measurement of singlet oxygen comprising said compound and a method for measurement of singlet oxygen using said compound. In particular, it is an object of the present invention to provide an agent for accurate measurement of singlet oxygen localized in particular cells or tissues in living bodies by a bioimaging technique.  
      The inventors of the present invention conducted various studied to achieve the foregoing objects. As a result, they found that a substantially non-fluorescent compound represented by the following general formula (I) efficiently reacts with singlet oxygen to give an endoperoxide compound (II) having superior light stability, and that the resulting specific anthracene derivative is highly water-soluble. They also found that singlet oxygen localized in living cells or tissues can be measured with extremely high specificity and sensitivity by using a compound represented by the general formula (I) as an agent for measurement of singlet oxygen. The present invention was achieved on the basis of these findings.  
      The present invention thus provide compounds represented by the following general formula (I):  
                 
 
 wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  independently represent a hydrogen atom, a halogen atom, a C 1-6  alkyl group, or a C 1-6  alkoxyl group, R 7  and R 8  independently represent a C 1-4  alkyl group, and R 9  represents a hydrogen atom, a C 1-12  alkanoyl group, or acetoxymethyl group, or salts thereof. 
 
      From another aspect of the present invention, there are also provided compounds represented by the following general formula (II):  
                 
 
 wherein R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  independently represent a hydrogen atom, a halogen atom, a C 1-6  alkyl group, or a C 1-6  alkoxyl group, R 17  and R 18  independently represent a C 1-4  alkyl group, and R 19  represents a hydrogen atom, a C 1-12  alkanoyl group, or acetoxymethyl group, or salts thereof. 
 
      From further aspects of the present invention, there are provided agents for measurement of singlet oxygen comprising a compound represented by the aforementioned formula (I) or a salt thereof, use of the compounds represented by the aforementioned formula (I) or salts thereof for the manufacture of the aforementioned agents for measurement of singlet oxygen; and methods for measuring singlet oxygen, which comprise the steps of, (a) reacting a compound of the aforementioned formula (I) or a salt thereof with singlet oxygen, and (b) measuring fluorescence of a compound of the aforementioned formula (II) or a salt thereof produced in the above step (a).  
      In addition to the above, there are also provided compounds represented by the following general formula (III):  
                 
 
 wherein R 21 , R 22 , R 23 , R 24 , R 25 , and R 26  independently represent a hydrogen atom, a halogen atom, a C 1-6  alkyl group, or a C 1-6  alkoxyl group, R 27  and R 28  independently represent a C 1-4  alkyl group, and R 29  and R 30  independently represent a C 1-12  alkanoyl group or acetoxymethyl group, and 
 
 compounds represented by the following general formula (IV):  
                 
 
 wherein R 31 , R 32 , R 33 , R 34 , R 35 , and R 36  independently represent a hydrogen atom, a halogen atom, a C 1-6  alkyl group, or a C 1-6  alkoxyl group, R 37  and R 38  independently represent a C 1-4  alkyl group, and R 39  and R 40  independently represent a C 1-12  alkanoyl group or acetoxymethyl group. The compounds represented by the formula (III) are also useful as agents for measurement of singlet oxygen. 
 
    
    
     BRIEF EXPLANATION OF THE DRAWINGS  
       FIG. 1  shows light stability of a compound represented by the formula (II) of the present invention (DMAX-EP) and a known compound (DPAX-1-EP).  
       FIG. 2  shows results of measurement of singlet oxygen using the compound of the present invention. In the figure, the arrow indicates a time when EP-1 was added. The solid line indicates the result obtained by the compound DMAX of the present invention, and the dotted line indicates the result obtained by the known compound (DPAX-1). 
    
    
     BEST MODE FOR CARRYING OUT THE INVENTION  
      The entire disclosure of Japanese Patent Application No. 2000-263067 (filed on Aug. 31, 2000) and the entire disclosure of Japanese Patent Application No. 2000-308581 (filed on Oct. 10, 2000) are incorporated by reference in the specification.  
      The terms used in this specification have the following meanings. An alkyl group or an alkyl moiety of an alkoxyl group may be linear, branched, or cyclic. For example, the term of C 1-6  alkyl group means a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms. More specifically, methyl group, ethyl group, n-propyl group, isopropyl group, cyclopropyl group, n-butyl group, sec-butyl group, tert-butyl group, cyclobutyl group, n-pentyl group, n-hexyl group, cyclohexyl group and the like may be used. As the alkyl group and the alkoxyl group, those having a linear or branched chain are preferred. As the halogen atom, although any of fluorine atom, chlorine atom, bromine atom, and iodine atom may be used, chlorine atom is preferred. The alkanoyl group may be either of linear or branched. As the alkanoyl group, for example, formyl group, acetyl group, propanoyl group and the like can be used. Acetyl group is preferred. As the C 1-4  alkyl group represented by R 7 , R 8 , R 17 , R 18 , R 27 , R 28 , R 87 , or R 88 , methyl group and ethyl group are preferred, and methyl group is particularly preferred.  
      In the formula (I), it is preferred that R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  are hydrogen atoms, or R 1 , R 3 , R 4 , and R 5  are hydrogen atoms, and R 2  and R 5  are chlorine atoms. It is preferred that R 7  and R 8  are methyl groups, and R 9  is a hydrogen atom, an acetyl group, or acetoxymethyl group.  
      In the formula (II), it is preferred that R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are hydrogen atoms, or R 11 , R 13 , R 14 , and R 15  are hydrogen atoms, and R 12  and R 15  are chlorine atoms. It is preferred that R 17  and R 18  are methyl groups, and R 19  is a hydrogen atom, an acetyl group, or acetoxymethyl group.  
      In the formula (III), it is preferred that R 21 , R 22 , R 23 , R 24 , R 25 , and R 26  are hydrogen atoms, or R 21 , R 23 , R 24 , and R 26  are hydrogen atoms, and R 22  and R 26  are chlorine atoms. It is preferred that R 27  and R 28  are methyl groups, and R 29  and R 30  are both acetyl groups or acetoxymethyl groups.  
      In the formula (IV), it is preferred that R 31 , R 32 , R 33 , R 34 , R 35 , and R 36  are hydrogen atoms, or R 31 , R 33 , R 34 , and R 36  are hydrogen atoms, and R 32  and R 35  are chlorine atoms. It is preferred that R 37  and R 38  are methyl groups, and R 39  and R 40  are both acetyl groups or acetoxymethyl groups.  
      Among the compounds of the present invention, preferred compounds include: 
      (1) a compound wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  are hydrogen atoms, R 7  and R 8  are methyl groups, and R 9  is a hydrogen atom;     (2) a compound wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  are hydrogen atoms, R 7  and R 8  are methyl groups, and R 9  is an acetyl group;     (3) a compound wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6  are hydrogen atoms, R 7  and R 8  are methyl groups, and R 9  is acetoxymethyl group;     (4) a compound wherein R 1 , R 3 , R 4 , and R 5  are hydrogen atoms, R 2  and R 5  are chlorine atoms, R 7  and R 8  are methyl groups, and R 9  is a hydrogen atom;     (5) a compound wherein R 1 , R 2 , R 4 , and R 6  are hydrogen atoms, R 2  and R 6  are chlorine atoms, R 7  and R 8  are methyl groups, and R 9  is an acetyl group;     (6) a compound wherein R 1 , R 3 , R 4 , and R 6  are hydrogen atoms, R 2  and R 5  are chlorine atoms, R 7  and R 8  are methyl groups, and R 9  is acetoxymethyl group;     (7) a compound wherein R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are hydrogen atoms, R 17  and R 18  are methyl groups, and R 19  is a hydrogen atom;     (8) a compound wherein R 11 , R 12 , R 13 , R 14 , R 15 , and R 16  are hydrogen atoms, R 17  and R 18  are methyl groups, and R 19  is an acetyl group;     (9) a compound wherein R 11 , R 12 , R 13 , R 14 , R 15 , and R 18  are hydrogen atoms, R 17  and R 13  are methyl groups, and R 19  is acetoxymethyl group;     (10) a compound wherein R 11 , R 13 , R 14 , and R 16  are a hydrogen atom, R 12  and R 16  are a chlorine atom, R 17  and R 18  are methyl group, and R 19  is a hydrogen atom;     (11) a compound wherein R 11 , R 18 , R 14 , and R 16  are hydrogen atoms, R 12  and R 16  are chlorine atoms, R 17  and R 18  are methyl groups, and R 19  is an acetyl group;     (12) a compound wherein R 11 , R 13 , R 14 , and R 16  are hydrogen atoms, R 12  and R 15  are chlorine atoms, R 17  and R 18  are methyl groups, and R 19  is acetoxymethyl group;     (13) a compound wherein R 21 , R 22 , R 23 , R 24 , R 25 , and R 26  are hydrogen atoms, R 27  and R 26  are methyl groups, and R 29  and R 30  are acetyl groups;     (14) a compound wherein R 21 , R 22 , R 23 , R 24 , R 25 , and R 26  are hydrogen atoms, R 27  and R 28  are methyl groups, and R 29  and R 30  are acetoxymethyl groups;     (15) a compound wherein R 21 , R 23 , R 24 , and R 26  are hydrogen atoms, R 22  and R 25  are chlorine atoms, R 27  and R 28  are methyl groups, and R 29  and R 30  are acetyl groups;     (16) a compound wherein R 21 , R 23 , R 24 , and R 26  are hydrogen atoms, R 22  and R 25  are chlorine atoms, R 27  and R 28  are methyl groups, and R 29  and R 30  are acetoxymethyl groups;     (17) a compound wherein R 31 , R 32 , R 33 , R 34 , and R 36  are hydrogen atoms, R and R 38  are methyl groups, and R 39  and R 40  are acetyl groups;     (18) a compound wherein R 31 , R 32 , R 33 , R 34 , R 35 , and R 36  are hydrogen atoms, R 37  and R 38  are methyl groups, and R 39  and R 40  are acetoxymethyl groups;     (19) a compound wherein R 31 , R 32 , R 34  and R 36  are hydrogen atoms, R 32  and R 36  are chlorine atoms, R 37  and R 38  are methyl groups, and R 39  and R 40  are acetyl groups; and     (20) a compound wherein R 31 , R 32 , R 34 , and R 36  are hydrogen atoms, R 32  and R 35  are chlorine atoms, R 37  and R 35  are methyl groups, and R 39  and R 40  are acetoxymethlyl groups. Among them, a particularly preferred compound is the aforementioned compound (1).    

      The compounds of the formula (I) and the formula (II) can exist as a base addition salt. Examples of the base addition salts include, for example, metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salt, ammonium salts, organic amine salts such as triethylamine salts, piperidine salts and morpholine salts and the like. However, salts of the compounds of the present invention are not limited to these examples. Among them, physiologically acceptable water-soluble base addition salts can suitably be used for the agent and method for measurement of the present invention. Further, the compounds of the formula (I) and the formula (II) in free forms or salts thereof may exist as hydrates or solvates, and any of these substances fall within the scope of the present invention. The types of solvents that form the solvates are not particularly limited. For example, solvents such as ethanol, acetone and isopropanol can be exemplified.  
      The compounds of the formula (I) and the formula (II) may have one or more asymmetric carbons depending on the type of the substituent(s), and optical isomers or diastereoisomers may exist. Further, depending on the type of R 1  and/or R 6 , or R 11  and/or R 16 , optical isomers due to rotation hindrance may exist. These isomers in pure forms, any mixtures of these isomers, racemates and the like fall within the scope of the present invention. In addition, the compounds of the formula (I) and the formula (II) of the present invention may form a lactone ring and exist as compounds having a structure corresponding to the fundamental structure of the compounds of the formula (III) or the formula (IV), or they may also exist as other tautomers. It should be understood that these compounds in which the lactone ring is formed and other isomers fall within the scope of the present invention. Optically active isomers based on the aforementioned lactone formation also fall within the scope of the present invention.  
      Methods for preparing the compounds of the present invention are not particularly limited. For example, the compounds of the present invention can be prepared by the method described in International Patent Publication WO99/51586. Further, the method for preparing the compounds of the present invention will be described more specifically and in more detail in examples of the specification. Therefore, those skilled in the art can prepare any of the compounds of the present invention by referring to the explanations of the manufacturing method mentioned in the above schemes and specific explanations in the examples, and by appropriately choosing starting materials and agents, and by suitably altering or modifying reaction conditions, reaction steps and the like as required. A target compound can sometimes be efficiently prepared by performing the reaction after protection of a certain functional group as required in the reaction steps. Detailed explanations of protective groups are given in, for example, Protective Groups in Organic Synthesis, T. W. Greene, John. Wiley &amp; Sons, Inc., 1981 and the like, and those skilled in the art can choose suitable protective groups.  
      In the above preparations, isolation and purification of the products can be performed by a suitable combination of techniques used in ordinary organic synthesis, for example, filtration, extraction, washing, dehydration, concentration, crystallization, various chromatography techniques and the like. The synthetic intermediates in the above steps can be used for the subsequent reactions without particular purification. Where preparation of a salt of the compound of the present invention is desired, when a salt of each compound is obtained in the above preparation, the resulting salt, per se, may be purified. When a compound in a free form is obtained, the compound in a free form can be dissolved or suspended in a suitable solvent and added with a base to form a salt, which may be purified as required.  
      The compounds represented by the aforementioned formula (I) and salts thereof have a property of reacting with singlet oxygen under a mild condition, for example, a physiological condition, to give a corresponding compound of the aforementioned formula (II) or a salt thereof. The compounds of the formula (I) and salts thereof are substantially non-fluorescent, whereas the compounds of the formula (II) and salts thereof have a property of emitting fluorescence with a high intensity. Therefore, by subjecting a compound of the aforementioned formula (I) or a salt thereof to reaction with singlet oxygen, and then measuring fluorescence of a produced compound of the aforementioned formula (II) or a salt thereof, singlet oxygen can be measured. The compounds of the formula (I) or salts thereof have a property that they do not substantially react with oxygen radicals and the like, but specifically react with singlet oxygen. Further, the compounds of the formula (II) and salts thereof have extremely high fluorescence intensity. Therefore, by using the compound of the formula (I) or a salt thereof as an agent for measurement of singlet oxygen, singlet oxygen localized in individual cells or in particular tissues can be accurately measured. The compounds of the formula (I) or salts thereof have a excellent property of being uniformly distributed in a cell without being localized in the cell membrane. Further, the compounds of the formula (II) and salts thereof generated by the reaction with singlet oxygen have sensitivity higher than the anthracene derivative described in International Patent Publication WO99/51586.  
      The term “measurement” used in the present specification should be construed in its broadest sense, including measurements performed for the purpose of quantification, qualification, diagnosis or the like, as well as tests or detections and the like. The method for measurement of singlet oxygen of the present invention generally comprises the steps of (a) reacting a compound of the aforementioned formula (I) or a salt thereof with singlet oxygen, and (b) measuring fluorescence of a compound of the aforementioned formula (II) or a salt thereof produced in the above step (a). The fluorescence of the compound of the aforementioned formula (II) or a salt thereof may be measured by an ordinary method. A method of measuring fluorescence spectrum in vitro, a method of measuring fluorescence spectrum in vivo by using a bioimaging technique and the like may be employed. For example, when quantification is desired, it is preferred to prepare a calibration curve beforehand according to a conventional method. As a quantitative singlet oxygen generation system, for example, the naphthalene endoperoxide system (Saito, I, et al., J. Am. Chem. Soc., 107, pp. 6329-6334, 1985) and the like can be used.  
      A compound of the formula (I) wherein R 9  is a C 1-12  alkanoyl group or acetoxymethyl group or a salt thereof, or a compound of the formula (III), after it passes through a cell membrane and is taken up into a cell, in which the alkanoyl group or acetoxymethyl group is hydrolyzed by an enzyme such as an intracellular esterase gives a hydrolyzed product [a compound of the formula (I) wherein R 9  is a hydrogen atom or a salt thereof]. The resulting hydrolyzed product reacts with singlet oxygen in the cell without being easily excreted extracellularly to give a compound of the formula (II) wherein R 19  is a hydrogen atom. Therefore, if these compounds are used as agents for the measurement, singlet oxygen localized in individual cells can be measured by a bioimaging technique with high sensitivity.  
      As the agent for measurement of singlet oxygen of the present invention; a compound of the formula (I) or a salt thereof or a compound of the aforementioned formula (III) per se may be used. They may also be used as a composition formulated with additives ordinarily used for preparation of agents, if desired. For example, as additives for use of the agent in a physiological condition, additives such as dissolving aids, pH modifiers, buffers, isotonic agents and the like can be used, and amounts of these additives can suitably be chosen by those skilled in the art. The compositions may be provided as compositions in appropriate forms, for example, powdery mixtures, lyophilized products, granules, tablets, solutions and the like. Since the method for measurement of singlet oxygen is specifically disclosed in International Patent Publication WO99/51586, those skilled in the art can use the agents for measurement of singlet oxygen of the present invention by referring to the aforementioned publication. The disclosure of International Patent Publication WO99/51586 is herein incorporated by reference.  
     EXAMPLES  
      The present invention will be more specifically explained with reference to the following examples. However, the scope of the present invention is not limited to the following examples.  
     Example 1  
     Preparation of Compounds of the Present Invention  
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     (1) Synthesis of 2,3-dibromoanthraquinone 3  
      1,2-Dibromobenzene 1 (6 ml) was added with pulverized phthalic anhydride 2 (2.24 g, 15.1 mmol) and aluminum chloride (III) (4.4 g, 33.0 mmol), and heated at 150° C. for 1 hour. The cooled reaction mixture was added with 2 N HCl, and extracted with benzene. The benzene layer was extracted with 2 M aqueous sodium hydroxide, and the aqueous layer was washed with ether, adjusted to about pH 2.5 with 6 M HCl, and extracted with ether. The organic layer was washed with saturated brine and dried over sodium sulfate, and ether was evaporated under reduced pressure. The resulting solid was dissolved in concentrated sulfuric acid (20 mL) and used without treatment in the subsequent reaction. The reaction mixture was gradually heated to 125° C. over 1 hour and then maintained at 125° C. for 30 minutes. The reaction mixture was cooled and poured into ice, and the precipitates were collected by filtration. The precipitates were dried and purified by silica gel chromatography (solvent: CH 2 Cl 2 /n-hexane 2/1) to obtain Compound 3 (1.38 g, yield: 25%, light yellow powder).  
       1 H NMR (CDCl 3 ): δ 7.84 (dd, 2H, J=3.1, 5.7 Hz), 8.32 (dd, 2H, J=3.1, 5.7 Hz), 8.53 (s, 2H)  
      MS (EI − ): 364:366:368=1:2:1 (M + )  
      m.p.: &gt;300° C.  
     (2) Synthesis of 2,3-dibromo-9,10-dimethyl-9,10-dibydroanthracene 4  
      Compound 3 (1.22 g, 3.33 mmol) was dissolved in distilled THF (150 ml). The solution was gradually added with methylmagnesium chloride. (3 M in THF, 4.5 ml) under argon atmosphere and refluxed with heating for 4 hours. The cooled reaction mixture was treated with aqueous saturated ammonium chloride, and THF was evaporated under reduced pressure. The remaining reaction mixture was extracted with methylene chloride, and the organic layer was washed with saturated brine and dried over sodium sulfate. The methylene chloride was evaporated under reduced pressure to obtain crude product 4. The crude product was purified by silica gel chromatography (solvent: CH 2 Cl 2 ) to obtain Compound 4 (995 mg, yield: 75%, light yellow powder).  
       1 H NMR (CDCl 3 ): cis: δ 1.63 (s, 6H), 7.41-7.45 (m, 2H), 7.79-7.83 (m, 2H), 8.11 (s, 2H), trans: δ 1.86 (s, 6H), 7.41-7.45 (m, 2H), 7.79-7.83 (m, 2H), 8.01 (s, 2H)  
      MS (EI − ): 396:398:400=1:2:1 (M + )  
     (3) Synthesis of 2,3-dibromo-9,10-dimethylanthracene 5  
      Compound 4 (1.08 g, 2.71 mmol) was dissolved in acetic acid (28 ml); added with tin(II) chloride dihydrate (12.8 g) and concentrated hydrochloric acid (12 ml) and refluxed with heating under argon atmosphere for 1 hour. The cooled reaction mixture was poured into water (500 ml), and the precipitates were collected by filtration. The precipitates were dried and purified by silica gel chromatography (solvent: CH 2 Cl 2 /hexane=1/2) to obtain Compound 5 (744 mg, yield: 78%, yellow powder).  
       1 H NMR (CDCl 3 ): δ 3.04 (5, 6H), 7.55 (dd, 2H, J=3.5, 7.0 Hz), 8.30 (dd, 2H, J=3.5, 7.0 Hz), 8.62 (s, 2H)  
      MS (EI − ): 362:364:366=1:2:1 (M − )  
     (4) Synthesis of 9,10-dimethylanthracene-2,3-dicarbonitrile 6  
      Compound 5 (730 mg, 2.00 mmol) was dissolved in distilled DMF (45 ml), added with copper(I) cyanide (694 mg, 7.74 mmol), and refluxed with heating under argon atmosphere for 9 hours. The reaction mixture was cooled and then added with 12.5% aqueous ammonia (90 ml), and the precipitates were collected by filtration. The precipitates were dried and then purified by silica gel chromatography (solvent. CH 2 Cl 2 /hexane=2/5) to obtain Compound 6 (255 mg, yield: 50%, yellow crystals).  
       1 H NMR (CDCl 3 ): δ 3.14 (s, 6H), 7.73 (dd, 2H, J=3.2, 6.8 Hz), 8.41 (dd, 2H, J=3.2, 6.8 Hz), 8.86 (s, 2H)  
      MS (EI + ): 256 (M + )  
      m.p.: 266° C. (decomp.)  
     (5) Synthesis of 9,10-dimethyl-2,3-anthracenedicarboxylic Acid 7  
      Compound 6 (330 mg, 1.29 mmol) was dissolved in 3 M butanolic potassium hydroxide (50 ml) and refluxed with heating under argon atmosphere for 10 hours. The cooled reaction mixture was treated with 2 N HCl and extracted with ether. The organic layer was washed with saturated brine and dried over sodium sulfate. The ether was evaporated under reduced pressure, and the residue was purified by silica gel chromatography (solvent: CH 2 Cl 2 /methanol=20/1) to obtain Compound 7 (268 mg, yield: 71%, yellow powder).  
       1 H NMR (DMSO-d 6 ): δ 3.08 (s, 6H), 7.66 (dd, 2H, J=1.6, 6.8 Hz), 8.43 (dd, 2H, J=1.6, 6.8 Hz), 8.66 (s, 2H)  
      MS (EI − : 294 (M − )  
     (6) Synthesis of 9,10-dimethyl-2,3-anthracenedicarboxylic Anhydride 8  
      Compound 7 (645 mg, 2.19 mmol) was added with acetic anhydride (110 ml) and refluxed with heating for 10 minutes. The reaction mixture was cooled to precipitate crystals, and the precipitates were collected by filtration to obtain Compound 8 (367 mg, yield: 61%, red crystals).  
       1 H NMR (CDCl 3 ): δ 3.23 (s, 6H), 7.73 (dd, 2H, J=1.5, 7.0 Hz), 8.44 (dd, 2H, J=1.5, 7.0 Hz), 9.12 (s, 2H)  
      MS (EI + ): 276 (M + )  
      m.p.: 278° C.  
     (7) Synthesis of DMAX-diAc 10  
      Resorcinol 9 (681 mg, 6.18 minor) was dissolved in methanesulfonic acid (6.6 ml) and added with Compound 8 (367 mg, 1.33 mmol). The reaction mixture was heated at 85° C. with light shielding under argon atmosphere for 24 hours. The cooled reaction mixture was poured into ice water (43 ml), and the precipitates were collected by filtration and dried. The resulting solid was dissolved in acetic anhydride (8 ml), added with pyridine (4 ml), and stirred at room temperature under argon atmosphere for 10 minutes. The reaction mixture was poured into 2% hydrochloric acid at 0° C. and extracted with methylene chloride. The organic layer was washed with saturated brine and dried over sodium sulfate. The methylene chloride was evaporated under reduced pressure, and the precipitates were purified by silica gel chromatography (solvent: CH 2 Cl 2 ). The product was recrystallized from benzene to obtain Compound 10 (294 mg, yield: 48%, yellow crystals).  
       1 H NMR (CDCl 3 ): δ 2.31 (s, 6H), 2.99 (s, 3H), 3.29 (s; 3H), 6.79 (dd, 2H, J=8.7, 2.2 Hz), 6.92 (d, 2H, J=8.7 Hz), 7.14 (d, 2H, J=2.2 Hz), 7.59-7.62 (m, 2H), 8.11 (s, 1H), 8.30-8.42 (m, 2H), 9.20 (6, 1H)  
      MS (FAB − ): 461 (M − +1)  
      m.p.: 280° C. (decomp.)  
     (8) Synthesis of DMAX 11  
      Compound 10 (30 mg, 65.1 μmol) was dissolved in THF (5 ml), methanol (5 ml), and distilled water (0.8 ml). This solution was added with commercially available aqueous ammonia (25-28%, 1.4 ml), and stirred at room temperature for 5 minutes. Then, the reaction mixture was filtered and diluted with distilled water (60 ml). The reaction mixture was adjusted to pH 2 with 10% HCl, and THF and methanol were evaporated under reduced pressure. The remaining reaction mixture was extracted with ether, washed with saturated brine, and dried over magnesium sulfate. The ether was evaporated under reduced pressure to obtain Compound 11 (18 mg, yield: 60%, reddish brown powder).  
       1 H NMR (DMSO-d 6 ): δ 3.15 (s, 3H), 3.17 (9, 3H), 6.49-6.52 (m, 2H), 6.65-6.69 (m, 4H), 7.63-767 (m, 2H), 8.14 (s, 1H), 8.35-8.50 (m, 2H), 9.09 (s, 1H)  
      MS (FAB − ): 461 (M − +1)  
      m.p.: 236° C. (decomp)  
     (9) Synthesis of DMAX-EP-diAc 12  
      A solution of Compound 11 (104 mg, 0.23 mmol) dissolved in dimethyl sulfoxide (DMSO, 20 ml) was added to Buffer A (180 ml, Buffer A: 9.3 mM sodium hydroxide, 4.8 mM sodium hydrogencarbonate, 9.4 mM sodium carbonate, and 138 mM sodium molybdate dihydrate). This reaction mixture was added with 30% aqueous hydrogen peroxide twice (5 ml each) with an interval of 15 minutes. The mixture was appropriately cooled so that the reaction temperature was not undesirably increased and maintained around 20° C. as near as possible. The reaction, mixture was made acidic with phosphoric acid and then extracted with ether. The organic layer was washed with saturated brine and dried over magnesium sulfate, and the ether was evaporated under reduced pressure. The resulting solid was added with acetic anhydride and pyridine and stirred at room temperature for 10 minutes. The reaction mixture was poured into 2% hydrochloric acid at 0° C. and extracted with methylene chloride. The organic layer was washed with saturated brine and dried over sodium sulfate. The methylene chloride was evaporated under reduced pressure, and the residue was purified by silica gel chromatography (solvent: CH 2 Cl 2 ) to obtain Compound 12 (59 mg, yield: 45%).  
       1 H NMR (CDCl 3 ): δ 2.06 (s, 3H), 2.26 (s, 3H), 2.28 (s, 3H), 2.33 (s, 3H), 6.67-6.74 (m, 2H), 6.84-6.99 (m, 2H), 7.06-7.13 (m, 2H), 7.14 (s, 1×), 7.30-7,49 (m, 4H), 8.01 (8, 1H)  
      MS (FAB − ): 577 (M + +1)  
     Example 2  
     Light Stability of DMAX-EP  
      5.0 μM aqueous solutions of DMAX-EP (endoperoxide of Compound 11 in the above scheme) and DPAX-1-EP (endoperoxide of Compound 13 described in International Patent Publication WO99/51586, Example 1) [0.1 M phosphate buffer (pH 7.4) containing 0.1% DMSO as a cosolvent]were each placed in a fluorescent cell and exposed to an excitation light of 491 nm at 37° C. with stirring, and fluorescence was measured at 520 nm by using a fluorometer while the solution was continuously exposed to the excitation light. The results are shown in  FIG. 1 . Photobleaching of DMAX-EP was 54 times slower than that of DPAX-1-EP, which verified excellent light stability.  
     Example 3  
     Measurement of Singlet Oxygen  
      Singlet oxygen was generated continuously with time under a neutral condition at 37° C. in given amounts by using a naphthalene endoperoxide compound EP-1 (Saito, I, et al., J. Am. Chem. Soc., 107, pp. 6329-6334, 1985) as a singlet oxygen generation system. Fluorescence was measured in the presence of DMAX and DPAX-1 [100 mM phosphate buffer (pH 7.4), DMSO (0.1%)]. The results are shown in  FIG. 2 . In the presence of DMAX, an increase of fluorescence intensity dependent on the generated amount of singlet oxygen Was observed as the concentration of EP-1 was increased from 0.1 mM to 0.5 mM and to 1.0 mM (The results were shown by the solid line in  FIG. 2 . EP-1 at each concentration was added into the system at each of the times indicated by arrows. Numerical values indicate EP-1 concentrations). Further, the increase of fluorescence intensity obtained by the addition of 0.5 mM EP-1 in the presence of DMAX was far larger than that obtained by the addition of 10 mM EP-1 in the presence of DPAX-1 (dotted line in the figure), which revealed that DMAX had much higher sensitivity than that of DPAX-1.  
     Industrial Applicability  
      The compounds of the present invention are useful as agents for measurement of singlet oxygen. The compounds have much higher sensitivity compared with conventional agents for the measurement with a similar structure, and have significantly suppressed photobleaching of fluorescent compounds to be measured. Therefore, the agents for measurement of singlet oxygen of the present invention are extremely useful as agents for accurately measuring singlet oxygen in biological samples.